trans-Vaccenic acid
Based on 1 publication(s) in Google Scholar
trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 693-72-1
- Formula: C18H34O2
- Molecular Weight:282.46
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) trans-Vaccenic acid
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
trans-Vaccenic acid is reduced in the rumen to form stearic acid or is desaturated by Δ9-desaturase in the mammary tissue to produce cis-9, trans-11 C18:2, which is an abundant conjugated Linoleic acid isomer in meat and milk[1].
trans-Vaccenic acid (0-200 μM; 24 h) inhibits NPC cell viability in a dose-dependent manner[2].
trans-Vaccenic acid (25-100 μM; 24 h) induces apoptosis in NPC cells in a dose-dependent manner. trans-Vaccenic acid significantly increases the levels of cleaved PARP and cleaved caspase-3 in a time-dependent manner[2].
trans-Vaccenic acid (25-100 μM; 24 h) induces apoptosis in NPC cells through Akt and bad inactivation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:The human NPC cell lines 5-8F and CNE-2
-
Concentration:0 μM, 25 μM, 50 μM, 100 μM, 200 μM
-
Incubation Time:24 h
-
Result:The growth inhibitory ratios of 5-8F cells treated with 25, 50, 100 and 200 μM were 10.8, 18.9, 49.3 and 80.2%, respectively, and those of CNE-2 cells were 7.9, 15.2, 45.3 and 70.5%, respectively.
-
Cell Line:The human NPC cell lines 5-8F and CNE-2
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:24 h
-
Result:Incubation of 5-8F cells with 25, 50 or 100 μM for 24 h caused 7.67, 12.9% or 35% increases in total apoptosis, respectively.
Similarly, after incubation with 25 50 or 100 μM CNE-2, the percentage of apoptotic cells was increased by 12.9, 15.1% or 22.3%, respectively. Significantly increased the levels of cleaved PARP and cleaved caspase-3 in a time-dependent manner.
-
Cell Line:The human NPC cell lines 5-8F and CNE-2
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:24 h
-
Result:Induced a decrease in Bad phosphorylation on Ser-136 and Ser-112 in a concentration-dependent manner.
Protein kinases such as Akt phosphorylate Bad at Ser136, thereby blocking Bad-induced apoptosis.
The expression levels of p-Akt were significantly reduced in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Obese JCR:LA-cp rats[3].
-
Dosage:1% w/w
-
Administration:Diet; for 8 weeks
-
Result:Reduced total body fat and decreased adipocyte size.
Increased metabolic rate concomitantly with an increased preference for whole-body glucose utilization for oxidation and increased insulin sensitivity.
Decreased nonalcoholic fatty liver disease activity scores and reduced hepatic and intestinal triglyceride secretion, while exerting differential transcriptional regulation of SREBP1 and FAS amongst other key genes in the liver and the intestine.
Chemical Information
-
CAS No. 693-72-1
-
Appearance Solid
-
Molecular Weight 282.46
-
Formula C18H34O2
-
Color White to off-white
-
SMILES
CCCCCC/C=C/CCCCCCCCCC(O)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Integrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites. [Abstract]2024 Nov;281(Pt 2):135992. PMID: 39414535
Solvent & Solubility
DMSO : 100 mg/mL (354.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.85 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Corn Oil
Solubility: 50 mg/mL (177.02 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li D, et al. Ruminal microbe of biohydrogenation of trans-vaccenic acid to stearic acid in vitro. BMC Res Notes. 2012 Feb 15;5:97. [Content Brief]
[2]. Song J, et al. Trans-vaccenic acid inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells via a mitochondrial-mediated apoptosis pathway. Lipids Health Dis. 2019 Feb 9;18(1):46. [Content Brief]
[3]. Jacome-Sosa MM, et al. Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome. J Nutr Biochem. 2014 Jul;25(7):692-701. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5403 mL | 17.7016 mL | 35.4032 mL | 88.5081 mL |
| 5 mM | 0.7081 mL | 3.5403 mL | 7.0806 mL | 17.7016 mL | |
| 10 mM | 0.3540 mL | 1.7702 mL | 3.5403 mL | 8.8508 mL | |
| 15 mM | 0.2360 mL | 1.1801 mL | 2.3602 mL | 5.9005 mL | |
| 20 mM | 0.1770 mL | 0.8851 mL | 1.7702 mL | 4.4254 mL | |
| 25 mM | 0.1416 mL | 0.7081 mL | 1.4161 mL | 3.5403 mL | |
| 30 mM | 0.1180 mL | 0.5901 mL | 1.1801 mL | 2.9503 mL | |
| 40 mM | 0.0885 mL | 0.4425 mL | 0.8851 mL | 2.2127 mL | |
| 50 mM | 0.0708 mL | 0.3540 mL | 0.7081 mL | 1.7702 mL | |
| 60 mM | 0.0590 mL | 0.2950 mL | 0.5901 mL | 1.4751 mL | |
| 80 mM | 0.0443 mL | 0.2213 mL | 0.4425 mL | 1.1064 mL | |
| 100 mM | 0.0354 mL | 0.1770 mL | 0.3540 mL | 0.8851 mL |